VIDEO: CAR T-cell construct will improve efficacy for CD58 loss, mutation
Click Here to Manage Email Alerts
Researchers successfully created a CAR T-cell construct to signal CD58 mutation or loss in patients with large B cell lymphomas, according to a presentation from the ASH Annual Meeting and Exposition.
“This is a great example of how we can use clinical data from patients treated with CAR T-cell therapy and discover a new mechanism that's leading to decreased efficacy and then design new CAR T-cell constructs that at least in vivo and in vitro, could work better in some of these patients,” Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, told Healio in a video interview.
Collapse
Majzner, RG et al. Abstract 556. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts